Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Screening.

P Boyle1

  • 1Division of Epidemiology and Biostatistics, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy.

The European Respiratory Journal. Supplement
|February 8, 2003
PubMed
Summary
This summary is machine-generated.

Advancing cancer screening requires methodological innovation. Developing true surrogate endpoints and integrating effective treatments are crucial for maximizing population-based screening program success.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intelligence and global health: assessing the role of open source and social media intelligence analysis in infectious disease outbreaks.

Zeitschrift fur Gesundheitswissenschaften = Journal of public health·2018
Same author

Cancer incidence in cohorts of workers in the rubber manufacturing industry first employed since 1975 in the UK and Sweden.

Occupational and environmental medicine·2017
Same author

Cancer mortality in cohorts of workers in the European rubber manufacturing industry first employed since 1975.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Muscle-building supplement use and increased risk of testicular germ cell cancer in men from Connecticut and Massachusetts.

British journal of cancer·2015
Same author

Notch-mediated expansion of cord blood progenitors: maintenance of transcriptional and epigenetic fidelity.

Leukemia·2015
Same author

Triple-negative breast cancer: epidemiological considerations and recommendations.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same journal

Current status of lung transplantation.

The European respiratory journal. Supplement·2003
Same journal

Treatment of chronic respiratory failure: lung volume reduction surgery versus rehabilitation.

The European respiratory journal. Supplement·2003
Same journal

Home ventilation.

The European respiratory journal. Supplement·2003
Same journal

Mechanical ventilation: invasive versus noninvasive.

The European respiratory journal. Supplement·2003
Same journal

Respiratory failure in chronic obstructive pulmonary disease.

The European respiratory journal. Supplement·2003
Same journal

Physical and biological triggers of ventilator-induced lung injury and its prevention.

The European respiratory journal. Supplement·2003
See all related articles

Area of Science:

  • Oncology
  • Clinical Trials Methodology
  • Public Health

Background:

  • Cancer screening is rapidly advancing with new technologies.
  • Evaluating these emerging technologies presents significant methodological challenges.
  • Current randomized trials are lengthy, complex, and often use mortality as the primary outcome.

Purpose of the Study:

  • To address the need for renewed methodological thinking in cancer screening evaluation.
  • To explore the development and use of biological markers as surrogate endpoints.
  • To optimize the effectiveness of population-based cancer screening programs.

Main Methods:

  • Reviewing current challenges in evaluating new cancer screening technologies.
  • Highlighting the limitations of traditional randomized trials.

Related Experiment Videos

  • Discussing the importance of surrogate endpoints and effective treatment integration.

    • Main Results:

    • New technologies necessitate novel evaluation methods to avoid obsolescence.
    • Biological markers as surrogate endpoints can reduce trial size and increase feasibility.
    • Screening effectiveness is intrinsically linked to the availability and quality of cancer treatment.

    Conclusions:

    • A critical re-evaluation of screening trial methodologies is urgently needed.
    • Surrogate endpoints are essential for efficient and feasible cancer screening trials.
    • Maximizing population screening outcomes requires seamless integration with excellent treatment strategies.